Table 2.
Baseline characteristics of children 5–11 and adolescents 12–20 years of age in the study of overall effectiveness, direct and indirect effect of the BNT162b2 vaccine on long COVID during the period when the Omicron variant was prevalent.
| Omicron study in children |
Omicron study in adolescents |
|||||
|---|---|---|---|---|---|---|
| Vaccinated (N = 101,277) | Unvaccinated (N = 87,617) | Overall (N = 188,894) | Vaccinated (N = 37,724) | Unvaccinated (N = 47,011) | Overall (N = 84,735) | |
| Age | ||||||
| Median [Q1, Q3] | 8 [6, 10] | 7 [6, 9] | 8 [6, 10] | 15 [13, 17] | 15 [13, 17] | 15 [13, 17] |
| Distribution | ||||||
| 5 | 14,831 (14.6%) | 18,260 (20.8%) | 33,091 (17.5%) | |||
| 6 | 14,424 (14.2%) | 15,771 (18.0%) | 30,195 (16.0%) | |||
| 7 | 14,142 (14.0%) | 13,143 (15.0%) | 27,285 (14.4%) | |||
| 8 | 14,027 (13.9%) | 11,545 (13.2%) | 25,572 (13.5%) | |||
| 9 | 14,245 (14.1%) | 10,445 (11.9%) | 24,690 (13.1%) | |||
| 10 | 14,484 (14.3%) | 9587 (10.9%) | 24,071 (12.7%) | |||
| 11 | 15,124 (14.9%) | 8866 (10.1%) | 23,990 (12.7%) | |||
| 12 | 8208 (21.8%) | 6972 (14.8%) | 15,180 (17.9%) | |||
| 13 | 5260 (13.9%) | 6538 (13.9%) | 11,798 (13.9%) | |||
| 14 | 4948 (13.1%) | 6288 (13.4%) | 11,236 (13.3%) | |||
| 15 | 4650 (12.3%) | 6331 (13.5%) | 10,981 (13.0%) | |||
| 16 | 4350 (11.5%) | 5953 (12.7%) | 10,303 (12.2%) | |||
| 17 | 4224 (11.2%) | 4963 (10.6%) | 9187 (10.8%) | |||
| 18 | 2631 (7.0%) | 3941 (8.4%) | 6572 (7.8%) | |||
| 19 | 1894 (5.0%) | 3510 (7.5%) | 5404 (6.4%) | |||
| 20 | 1559 (4.1%) | 2515 (5.3%) | 4074 (4.8%) | |||
| Gender | ||||||
| Female | 49,080 (48.5%) | 41,313 (47.2%) | 90,393 (47.9%) | 20,617 (54.7%) | 25,109 (53.4%) | 45,726 (54.0%) |
| Male | 52,197 (51.5%) | 46,304 (52.8%) | 98,501 (52.1%) | 17,107 (45.3%) | 21,902 (46.6%) | 39,009 (46.0%) |
| Ethnicity | ||||||
| White | 22,763 (22.5%) | 35,040 (40.0%) | 57,803 (30.6%) | 9532 (25.3%) | 22,538 (47.9%) | 32,070 (37.8%) |
| Black/AA | 19,547 (19.3%) | 17,902 (20.4%) | 37,449 (19.8%) | 9750 (25.8%) | 9499 (20.2%) | 19,249 (22.7%) |
| Hispanic | 40,242 (39.7%) | 22,020 (25.1%) | 62,262 (33.0%) | 13,506 (35.8%) | 9389 (20.0%) | 22,895 (27.0%) |
| Asian/PI | 8136 (8.0%) | 2904 (3.3%) | 11,040 (5.8%) | 1734 (4.6%) | 1153 (2.5%) | 2887 (3.4%) |
| Multiple | 2317 (2.3%) | 2419 (2.8%) | 4736 (2.5%) | 662 (1.8%) | 920 (2.0%) | 1582 (1.9%) |
| Other/Unknown | 8272 (8.2%) | 7332 (8.4%) | 15,604 (8.3%) | 2540 (6.7%) | 3512 (7.5%) | 6052 (7.1%) |
| Hospital | ||||||
| A | 5167 (5.1%) | 8083 (9.2%) | 13,250 (7.0%) | 2183 (5.8%) | 4623 (9.8%) | 6806 (8.0%) |
| B | 14,578 (14.4%) | 10,424 (11.9%) | 25,002 (13.2%) | 5905 (15.7%) | 5526 (11.8%) | 11,431 (13.5%) |
| C | 6081 (6.0%) | 5947 (6.8%) | 12,028 (6.4%) | 1870 (5.0%) | 3438 (7.3%) | 5308 (6.3%) |
| D | 3265 (3.2%) | 4092 (4.7%) | 7357 (3.9%) | 1534 (4.1%) | 3821 (8.1%) | 5355 (6.3%) |
| E | 582 (0.6%) | 1502 (1.7%) | 2084 (1.1%) | 255 (0.7%) | 1605 (3.4%) | 1860 (2.2%) |
| F | 4853 (4.8%) | 2621 (3.0%) | 7474 (4.0%) | 652 (1.7%) | 1462 (3.1%) | 2114 (2.5%) |
| G | 1026 (1.0%) | 2246 (2.6%) | 3272 (1.7%) | 662 (1.8%) | 2409 (5.1%) | 3071 (3.6%) |
| H | 1200 (1.2%) | 1727 (2.0%) | 2927 (1.5%) | 757 (2.0%) | 1618 (3.4%) | 2375 (2.8%) |
| I | 5893 (5.8%) | 8899 (10.2%) | 14,792 (7.8%) | 2116 (5.6%) | 3619 (7.7%) | 5735 (6.8%) |
| J | 10,309 (10.2%) | 9539 (10.9%) | 19,848 (10.5%) | 3813 (10.1%) | 4307 (9.2%) | 8120 (9.6%) |
| K | 39,011 (38.5%) | 12,749 (14.6%) | 51,760 (27.4%) | 16,144 (42.8%) | 6422 (13.7%) | 22,566 (26.6%) |
| L | 1895 (1.9%) | 3340 (3.8%) | 5235 (2.8%) | 1063 (2.8%) | 3103 (6.6%) | 4166 (4.9%) |
| M | 1356 (1.3%) | 5821 (6.6%) | 7177 (3.8%) | 770 (2.0%) | 5058 (10.8%) | 5828 (6.9%) |
| N | 433 (0.4%) | 1142 (1.3%) | 1575 (0.8%) | |||
| O | 1626 (1.6%) | 2555 (2.9%) | 4181 (2.2%) | |||
| P | 2700 (2.7%) | 2936 (3.4%) | 5636 (3.0%) | |||
| Q | 1302 (1.3%) | 3994 (4.6%) | 5296 (2.8%) | |||
| Entry time | ||||||
| 01/2022 | 54,823 (54.1%) | 31,111 (35.5%) | 85,934 (45.5%) | 17,583 (46.6%) | 16,438 (35.0%) | 34,021 (40.1%) |
| 02/2022 | 19,133 (18.9%) | 15,962 (18.2%) | 35,095 (18.6%) | 7425 (19.7%) | 8231 (17.5%) | 15,656 (18.5%) |
| 03/2022 | 9420 (9.3%) | 11,456 (13.1%) | 20,876 (11.1%) | 4136 (11.0%) | 6190 (13.2%) | 10,326 (12.2%) |
| 04/2022 | 4891 (4.8%) | 7551 (8.6%) | 12,442 (6.6%) | 2422 (6.4%) | 4660 (9.9%) | 7082 (8.4%) |
| 05/2022 | 4160 (4.1%) | 7982 (9.1%) | 12,142 (6.4%) | 2148 (5.7%) | 4384 (9.3%) | 6532 (7.7%) |
| 06/2022 | 4565 (4.5%) | 7291 (8.3%) | 11,856 (6.3%) | 2162 (5.7%) | 3752 (8.0%) | 5914 (7.0%) |
| 07/2022 | 4285 (4.2%) | 6264 (7.1%) | 10,549 (5.6%) | 1848 (4.9%) | 3356 (7.1%) | 5204 (6.1%) |
| Obesity | ||||||
| Nonobese | 34,372 (33.9%) | 38,168 (43.6%) | 72,540 (38.4%) | 11,249 (29.8%) | 19,806 (42.1%) | 31,055 (36.6%) |
| Obese | 55,691 (55.0%) | 40,622 (46.4%) | 96,313 (51.0%) | 21,757 (57.7%) | 21,651 (46.1%) | 43,408 (51.2%) |
| Unknown | 11,214 (11.1%) | 8827 (10.1%) | 20,041 (10.6%) | 4718 (12.5%) | 5554 (11.8%) | 10,272 (12.1%) |
| PMCA | ||||||
| 0 | 78,261 (77.3%) | 59,388 (67.8%) | 137,649 (72.9%) | 28,138 (74.6%) | 30,080 (64.0%) | 58,218 (68.7%) |
| 1 | 14,888 (14.7%) | 15,513 (17.7%) | 30,401 (16.1%) | 6016 (15.9%) | 8789 (18.7%) | 14,805 (17.5%) |
| 2 | 8128 (8.0%) | 12,716 (14.5%) | 20,844 (11.0%) | 3570 (9.5%) | 8142 (17.3%) | 11,712 (13.8%) |
| Negative tests prior entry | ||||||
| 0 | 72,618 (71.7%) | 45,099 (51.5%) | 117,717 (62.3%) | 29,406 (78.0%) | 25,020 (53.2%) | 54,426 (64.2%) |
| 1 | 19,079 (18.8%) | 24,973 (28.5%) | 44,052 (23.3%) | 5833 (15.5%) | 13,486 (28.7%) | 19,319 (22.8%) |
| 2 | 5893 (5.8%) | 9905 (11.3%) | 15,798 (8.4%) | 1561 (4.1%) | 4750 (10.1%) | 6311 (7.4%) |
| ≥3 | 3687 (3.6%) | 7640 (8.7%) | 11,327 (6.0%) | 924 (2.4%) | 3755 (8.0%) | 4679 (5.5%) |